CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 372 enrolled
Drug / intervention
HPV vaccine, Gardasil 9 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01824537
NCT01824537Phase 4Completed

Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples

McGill University·interventional·Posted Apr 4, 2013·Updated Mar 19, 2025

In Brief

A Phase 4 clinical trial evaluating HPV vaccine, Gardasil 9 and Hepatitis A vaccine for Human Papillomavirus Infection. Completed, enrolled 372 participants across 1 site.

Detailed Summary

Human papillomavirus (HPV) is a member of the Papillomaviridae family of DNA viruses that is capable of infecting humans. HPV infection can cause cancers of the cervix, vulva, vagina, and anus in women or cancers of the anus and penis in men. Two prophylactic vaccines have been proven to be highly effective in preventing the acquisition of HPV infection and the genital precancerous lesions caused by it. However, we do not know yet if a previously infected individual, once vaccinated, would be less infective to her or his sexual partner. We plan to conduct a study, called Transmission Reduction And Prevention with HPV vaccination (TRAP-HPV) study to answer this question. It will include 500 sexually active couples\* (total of 1000 individuals) in university student health clinics in Montreal (age 18-45 years). It will be a randomized placebo-controlled, double-blinded intervention trial. Study participants will be followed up to 12 months. Behavioural and biological data will be collected at the time of study enrolment, then at months 2, 4, 6, 9 and 12 post-enrolment. The results of this trial will be invaluable in informing policies regarding vaccination of women and men.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 4, 2013
Enrollment StartJan 1, 2014
Primary CompletionNov 18, 2022
TodayJul 2, 2026
Enrollment to primary: 8.9 yearsPosted 13.2 years ago

Interventions

HPV vaccine, Gardasil 9biological

Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Avaxim).

Hepatitis A vaccinebiological

Provided by Sanofi Pasteur.